Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydromethylthionine SCHEMBL29356148 | 0.89 | SNCA (0.50) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL109756 | 0.89 | SNCA (0.50) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL12592446 | 0.89 | SNCA (0.50) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL31159642 | 0.88 | SNCA (0.48) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL25194477 | 0.88 | SNCA (0.48) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL23683393 | 0.88 | SNCA (0.48) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL12470963 | 0.88 | SNCA (0.48) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL31159649 | 0.88 | SNCA (0.48) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL31159644 | 0.88 | SNCA (0.48) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 | |
| Hydromethylthionine SCHEMBL25199191 | 0.88 | SNCA (0.48) | TDP1MAPK1CYP3A4ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009007376-A1 | PHARMACEUTICAL COMPOSITIONS FOR PERORAL ADMINISTRATION OF PHENOTHIAZINE DYESTUFFS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2009-01-15 | — | — | WO | claimed |
| WO-2007144048-A2 | PRESENTATION FORM FOR THE ORAL ADMINISTRATION OF PHENOTHIAZINE DYES, ITS PRODUCTION AND USE | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG (AT) | 2007-12-21 | — | — | WO | claimed |
| US-20170050044-A1 | Integumentary System Therapy | LEBOVITZ RUSSELL M (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2017015174-A1 | INTEGUMENTARY SYSTEM THERAPY | LEBOVITZ RUSSELL M (US) | 2017-01-26 | — | — | WO | disclosed |
| US-7893054-B2 | administering to subject in need thereof a medicament comprising a diaminophenothiazine; results in blocking, modulating or inhibiting induced conformational polymerisation of proteinaceous structures such as beta -amyloid plaques and neurofibrillary tangles in the brains of affected patient | WISTA LABORATORIES LTD. (SG) | 2011-02-22 | — | — | US | disclosed |
| EP-1352077-B1 | MATERIALS AND METHODS RELATING TO PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASE | WISTA LAB LTD (SG) | 2010-10-06 | — | — | EP | disclosed |
| US-20090075984-A1 | Materials and methods relating to protein aggregation in neurodegenerative disease | WISTA LABORATORIES, LTD. | 2009-03-19 | — | — | US | disclosed |
| WO-2009007376-A1 | PHARMACEUTICAL COMPOSITIONS FOR PERORAL ADMINISTRATION OF PHENOTHIAZINE DYESTUFFS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2009-01-15 | — | — | WO | disclosed |
| US-7335505-B2 | Materials and methods relating to protein aggregation in neurodegenerative disease | WISTA LABORATORIES LTD. (SG) | 2008-02-26 | — | — | US | disclosed |
| WO-2007144048-A2 | PRESENTATION FORM FOR THE ORAL ADMINISTRATION OF PHENOTHIAZINE DYES, ITS PRODUCTION AND USE | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG (AT) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050044-A1 | Integumentary System Therapy | OTC, SUCLG1, TYR | TDP1 566/4885MAPK1 3165/4885CYP3A4 2921/4885 |
| US-20090075984-A1 | Materials and methods relating to protein aggregation in neurodegenerative disease | MAPT, PRNP, HTT | TDP1 173/4885MAPK1 3424/4885CYP3A4 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.